Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy

Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy

This study aimed to evaluate the outcomes and identify the predictive factors of a bladder-preservation approach incorporating maximal transurethral resection of bladder tumor (TURBT) coupled with either pembrolizumab or chemotherapy for patients diagnosed with muscle-invasive bladder cancer (MIBC)...

Full description

Bibliographic Details
Main Authors:	Pei-Hung Chang, Hung-Yi Chen, Yueh-Shih Chang, Po-Jung Su, Wen-Kuan Huang, Cheng-Feng Lin, Jason Chia-Hsun Hsieh, Chun-Te Wu
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Cancers
Subjects:	bladder preservation neoadjuvant chemotherapy pembrolizumab muscle-invasive bladder cancer clinical complete remission
Online Access:	https://www.mdpi.com/2072-6694/16/5/894

Similar Items

Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer
by: Ryohta Nakamura, et al.
Published: (2023-01-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
by: Ahmed Eldefrawy, et al.
Published: (2012-01-01)

A case of neoadjuvant chemotherapy‐resistant muscle‐invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy
by: Ichiro Yonese, et al.
Published: (2024-01-01)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
by: Dalia Elsayed, et al.
Published: (2023-04-01)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
by: Chinmayee Agrawal, et al.
Published: (2020-07-01)

Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations
by: Hye Won Lee, et al.
Published: (2023-02-01)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
by: Hyun Hwan Sung, et al.
Published: (2022-03-01)

Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
by: Kari T. Syvänen, et al.
Published: (2014-05-01)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
by: Arthur Peyrottes, et al.
Published: (2021-07-01)

Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience
by: Ibrahim El Halabi, et al.
Published: (2020-01-01)

Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis
by: Yusuke Goto, et al.
Published: (2022-07-01)

Evaluation of Neoadjuvant Chemotherapy in Treatment of Muscle Invasive Urothelial Bladder Tumors in Upper Egypt
by: Mohamed Khateeb, et al.
Published: (2017-12-01)

Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study
by: Sujun Han, et al.
Published: (2023-06-01)

A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer
by: Chinna Babu Dracham, et al.
Published: (2022-07-01)

Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
by: Bryce Baird, et al.
Published: (2023-08-01)

Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report
by: Gan Du, et al.
Published: (2024-03-01)

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
by: Daiki Ikarashi, et al.
Published: (2020-09-01)

Successful treatment of metastatic bladder pleomorphic giant cell carcinoma with pembrolizumab
by: Kunihisa Nezu, et al.
Published: (2021-07-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Bladder triplication associated with exstrophy variant
by: Monica Salgado-Diaz, et al.
Published: (2023-11-01)

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature
by: Jie Wu, et al.
Published: (2022-04-01)

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
by: F. J. Hinsenveld, et al.
Published: (2021-10-01)

Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
by: Daniel Au, et al.
Published: (2021-07-01)

Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes
by: Dellis A, et al.
Published: (2021-07-01)

Single Acceptance Sampling Plan Based on Truncated-life Tests for the Exponentiated Moment Exponential Distribution With Application in Bladder Cancer Data
by: Zainalabideen AL-Husseini, et al.
Published: (2023-08-01)

The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
by: Oktay Üçer
Published: (2016-04-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
by: Lanpeng Lu, et al.
Published: (2023-11-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy
by: Xinxin Zhang, et al.
Published: (2024-04-01)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
by: David D'Andrea, et al.
Published: (2022-07-01)

Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020
by: Neal S. Chawla, et al.
Published: (2020-01-01)

A Case with Rectal Cancer Relapses After Clinical Complete Remission Following Neoadjuvant Chemoradiotherapy
by: Zhang PB, et al.
Published: (2019-12-01)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
by: Evanguelos Xylinas, et al.
Published: (2016-09-01)

A rare case of small cell carcinoma of urinary bladder in a bladder diverticulum: Case report and review of literature
by: Kandarp Priyakant Parikh, et al.
Published: (2018-01-01)

Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer
by: Safiya Karim, et al.
Published: (2019-10-01)

Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab
by: K. Reuthner, et al.
Published: (2024-02-01)